Poland · Advertising framework
Paid social campaigns for pharmacies and health retail in Poland
General market orientation, not campaign clearance. Research scope and dates
Key restrictions and conditions
Pharmacy advertising is in a documented legislative transition
Legal requirement — paraphrased
The published Pharmaceutical Law text contains a blanket pharmacy-advertising ban; the CJEU found that blanket restriction incompatible with EU law in June 2025. Neither the old wording nor the judgment alone provides a complete campaign rule.
The official process record rechecked on 25 October 2026 records acceptance of Senate amendments on 22 October and transmission for presidential signature on 23 October. The retrieved record does not establish promulgation or commencement. Searches of official publication and presidential sources did not supply a verified effective act; this is an unresolved evidence condition, not proof that no publication exists.
Sources: Pharmaceutical Law — consolidated text, Dz.U. 2026 item 612; CJEU — Case C-200/24, pharmacy advertising judgment, 19 June 2025; Sejm official API — Pharmacy advertising amendment, process 3002; Senate — Pharmacy advertising amendment, October 2026 proceedings · Pharmaceutical Law Article 94a; C-200/24; process 3002
Product and service rules
Separate pharmacy promotion from advertising each stocked product
Editorial overview
A lawful product advertisement does not automatically clear promotion of the pharmacy, and a pharmacy advertisement does not clear prescription-medicine promotion. For each promoted item, apply the corresponding medicine, device, supplement or cosmetic rules.
General health retail is not automatically a licensed pharmacy. Review the actual operator, service and assortment. Do not present a draft fine or a draft restriction from the 2026 amendment as a rule already in force.
Sources: Pharmaceutical Law — consolidated text, Dz.U. 2026 item 612; Medical Devices Act — consolidated working text based on Dz.U. 2024 item 1620; GIS — Food labelling, presentation and advertising; Regulation (EU) No 655/2013 — Common criteria for cosmetic claims; Sejm official API — Pharmacy advertising amendment, process 3002 · Product-specific regimes; process 3002
Channel rules
Make the overall message truthful and commercially identifiable
Legal requirement — paraphrased
Misleading claims, material omissions, hidden commercial intent and aggressive consumer marketing are prohibited. Assess visuals, comparisons, qualifications and the impression on vulnerable consumers. Do not falsely claim that a product cures illness.
Editorial control: retain substantiation before publication, remove fabricated urgency or authority badges, and check that qualifications do not contradict the headline. Paying to publish apparently independent advice must not conceal its commercial nature.
Sources: Act on Counteracting Unfair Market Practices — consolidated text, Dz.U. 2023 item 845 · Articles 4–9; Article 7 hidden advertising and false cure claims
Check price reductions only after establishing that promotion is lawful
Legal requirement — paraphrased
Where an advertisement announces a reduction for a good or service, state the relevant lowest price from the preceding 30 days alongside the reduced price. For a shorter selling history, use the lowest price since sales began; special rules apply to rapidly perishable goods.
This consumer-information rule does not permit a discount or purchasing incentive prohibited by medicine or service rules. As an editorial check, make the total scope and extra charges clear.
Sources: UOKiK — Information about price reductions · Price Information Act Article 4 as explained by UOKiK
Keep reviews genuine and explain verification
Legal requirement — paraphrased
Do not publish, commission or distort false consumer recommendations. If making consumer reviews available, explain whether and how their origin is verified. Do not claim authentic-user verification without reasonable, proportionate checks.
Selecting a patient or customer story for advertising also requires checking the sector's claims and endorsement restrictions. A genuine testimonial can still contain an unlawful health claim.
Sources: UOKiK — False reviews? Stop!; Act on Counteracting Unfair Market Practices — consolidated text, Dz.U. 2023 item 845 · Unfair-practices Act Articles 6–7; UOKiK reviews guidance
Keep health data out of routine advertising workflows
Legal requirement — paraphrased
Establish a lawful processing basis, transparency and purpose limits. Health/genetic data also require a valid Article 9 condition; a treatment relationship does not automatically justify marketing reuse. Honour direct-marketing objections and withdrawable consent.
Editorial safeguard: keep symptoms, diagnoses, test results and appointment details out of advertising pixels, URLs, audience uploads and creator briefs unless a separately assessed lawful arrangement permits the processing.
Sources: Regulation (EU) 2016/679 — General Data Protection Regulation · Articles 5–7, 9, 13–14 and 21
Assess cookies, pixels and device access separately
Legal requirement — paraphrased
Prior information and consent are required for terminal storage/access unless a statutory exception applies, such as what is necessary for transmission or a service requested by the user. Ordinary advertising tracking should not be treated as necessary merely because it funds the website.
As an implementation control, test the consent mechanism before loading advertising tags and keep the privacy-processing assessment separate from the cookie-consent check.
Sources: Electronic Communications Law — Dz.U. 2024 item 1221 · Article 399
Treat boosted content as a full advertisement
Editorial recommendation
Review the paid creative, caption, account identity, placement variants and landing page. Do not assume platform acceptance establishes legal permission. A boosted creator post also needs the influencer-disclosure analysis; this channel does not erase it.
Online platforms must identify ads and their beneficiary/payer, and must not use sensitive-data profiling for ads or profiling-based targeting of recipients they know with reasonable certainty are minors. As an advertiser, supply accurate identity information and select a lawful targeting arrangement.
Sources: Regulation (EU) 2022/2065 — Digital Services Act; UOKiK — Influencer marketing recommendations and FAQ · DSA Articles 26 and 28; UOKiK guidance
Campaign workflow
Keep one campaign evidence and approval record
Editorial recommendation
Recommended workflow: record the exact offer and legal classification, advertiser, selected channel and creative formats; list permitted claims and evidence; review the Polish execution and destination; record sign-off, publication and corrections.
Keep the source date with the rule. Recheck legislation flagged as changing, especially pharmacy advertising. Preserve statutory archive periods where they apply; this suggested general workflow does not create a universal retention period.
Sources: URPL — Advertising medical devices; Sejm official API — Pharmacy advertising amendment, process 3002 · Specific retention and legislative-watch sources; workflow is editorial
Pre-publication checklist
- Resolve the pharmacy amendment's promulgation and commencement before approving a pharmacy campaign.
- Review every tracking event and audience input for health-data disclosure.
- Record the category gate before reviewing the channel.
- Approve the final creative, disclosure, targeting and landing page together.
- Assign an owner for corrections, expiry of claims and legislative updates.
Scope and unresolved questions
- Rechecked 25 October 2026: process 3002 ends with transmission for presidential signature on 23 October. Before stating the new pharmacy-advertising permissions as effective, obtain the signed final text, Journal of Laws item and commencement calculation. Do not substitute a bill summary or parliamentary adoption date.
- Check the chosen platform/provider's current health-advertising, tracking and targeting policies for the actual account and country. This source pack covers legal/regulator rules, not every vendor policy.
Research scope, introduction and dates
For pharmacies and health retail in paid social campaigns in Poland, separate promotion of the outlet from promotion of its stocked products. The framework preserves the documented legislative-transition issue so that an amendment in progress is not mistaken for an effective advertising permission.
For paid social, review each placement variant as well as the caption, advertiser identity, audience setup and landing page. Boosted creator content also brings the commercial relationship and its disclosure into the assessment.
General market orientation, not legal, regulatory or medical advice, a complete compliance plan or clearance of an advertisement. Actual requirements depend on the specific offer and campaign.
Resolve product and service restrictions before choosing a channel
Editorial overview
A platform label, newsletter consent, an advertising warning or a publisher's acceptance does not create permission to advertise. Apply the selected product/service gate first; if public promotion is prohibited, use this guide to identify the restriction and alternatives for specialist review.
This English guide describes Polish requirements. Required Polish warning text and locally understandable disclosure remain necessary where the law requires them.
Sources: Pharmaceutical Law — consolidated text, Dz.U. 2026 item 612; Healthcare Activity Act — consolidated text, Dz.U. 2026 item 156; Medical Devices Act — consolidated working text based on Dz.U. 2024 item 1620 · Product/service rules referenced in matching modules
Identify the regulated service and any separately promoted products
Editorial overview
A clinic, individual professional, treatment, pharmacy and wellness operator do not share one advertising permission. Identify who provides the service and whether it constitutes healthcare activity.
A promoted medicine, device, cosmetic or supplement needs the corresponding product review as well. Calling a post educational or using an influencer does not settle its legal classification.
Sources: Healthcare Activity Act — consolidated text, Dz.U. 2026 item 156; Pharmaceutical Law — consolidated text, Dz.U. 2026 item 612; Medical Devices Act — consolidated working text based on Dz.U. 2024 item 1620 · Healthcare Activity Act Article 14; Pharmaceutical Law Article 52; Device Act Article 58
Sources
- Pharmaceutical Law — consolidated text, Dz.U. 2026 item 612
Consolidation reflects 8 April 2026. Later amendments exist; pharmacy advertising must also be read with the CJEU judgment and the October 2026 legislative tracker in the pharmacy framework. This is a targeted advertising review, not an audit of the entire Act.
- CJEU — Case C-200/24, pharmacy advertising judgment, 19 June 2025
Press release summarises the judgment. The incompatibility finding is not blanket approval of every pharmacy campaign.
- Sejm official API — Pharmacy advertising amendment, process 3002
Follow-up review of the cited issue on 25 October 2026; scope and remaining conditions are recorded in the modules and review register.
- Senate — Pharmacy advertising amendment, October 2026 proceedings
Use the later Sejm process record for subsequent progress. Proposed restrictions and proposed fines are not current law merely because adopted by Parliament.
- Healthcare Activity Act — consolidated text, Dz.U. 2026 item 156
Public information must not have advertising characteristics. Information supplied at a patient's request under paragraph 2 is a different context.
- Medical Devices Act — consolidated working text based on Dz.U. 2024 item 1620
The inspected PDF is dated 19 November 2024. Advertising provisions were cross-checked against the current URPL advertising overview; recheck amendments before campaign sign-off.
- GIS — Food labelling, presentation and advertising
- Regulation (EU) No 655/2013 — Common criteria for cosmetic claims
- Act on Counteracting Unfair Market Practices — consolidated text, Dz.U. 2023 item 845
- UOKiK — Information about price reductions
- UOKiK — False reviews? Stop!
The 30 July 2024 announcement also describes enforcement decisions; their subsequent appeal status is not asserted here.
- Regulation (EU) 2016/679 — General Data Protection Regulation
A healthcare-processing basis does not automatically authorise advertising use.
- Electronic Communications Law — Dz.U. 2024 item 1221
Original official text checked for these provisions. The Act has later amendments; this is a targeted review of the cited rules, not a complete consolidation audit.
- Regulation (EU) 2022/2065 — Digital Services Act
The cited advertising duties address online-platform providers; they are not a claim that every advertiser is itself a platform provider.
- UOKiK — Influencer marketing recommendations and FAQ
Recommendations explain the authority's approach; do not present every implementation recommendation as statutory wording.
- URPL — Advertising medical devices
From framework to action
Local expertise in Poland
Find support with medical and health marketing, marketing and sales advice, or organizing your business and coordinating projects in Poland.
Medical & health marketing
No partners listed in this category yet.
Marketing & sales advisory
Marketing & sales advisory
Casbeg
Marketing and sales consulting for businesses in Poland: strategy, commercial processes, lead generation and CRM implementation.
View partner profileBusiness & project coordination
No partners listed in this category yet.
Join the local partner directory
Would you like your company to be listed?
Talk to us about the terms of a listing. Leave your details and we will get in touch.